Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 1:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 165 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buprenorphine and Naloxone Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept

NCT03604159
View directory record Official record
Conditions
Opioid Dependence
Interventions
Buprenorphine Extended Release, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 11, 2026, 1:06 PM EDT
Completed Phase 2 Interventional Results available

Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study

NCT03026790
View directory record Official record
Conditions
Chronic Pain
Interventions
Medication management, Non-pharmacological pain management, Buprenorphine-Naloxone
Other · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years and older
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 11, 2026, 1:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder

NCT04818086
View directory record Official record
Conditions
Drug Interaction, Analgesics, Opioid Use Disorder
Interventions
Lemborexant, Placebo, Buprenorphine-naloxone
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 11, 2026, 1:06 PM EDT
Completed Phase 1 Interventional

Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution

NCT01560221
View directory record Official record
Conditions
Substance-related Disorders, HIV Risk Behavior
Interventions
Therapeutic Workplace, Methadone, Buprenorphine
Behavioral · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 11, 2026, 1:06 PM EDT
Completed Phase 1Phase 2 Interventional

CBT4CBT for Office Based Buprenorphine

NCT03580902
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
CBT4CBT-Buprenorphine, Buprenorphine/naloxone
Behavioral · Drug
Lead sponsor
CBT4CBT, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 11, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

NCT01846455
View directory record Official record
Conditions
Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma
Interventions
2.0mg Buprenorphine/0.5mg Naloxone, Promethazine
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Hialeah, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 11, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Results available

Dane County Drug Court Study for Addicted Offenders

NCT01843751
View directory record Official record
Conditions
Opioid Dependence
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 11, 2026, 1:06 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars

NCT02161354
View directory record Official record
Conditions
Dental Pain
Interventions
NTC-510 capsules, Placebo Capsules, NTC-510A Capsules
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 11, 2026, 1:06 PM EDT
Completed Not applicable Interventional Results available

SMART Effectiveness Trial

NCT04464421
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Dependence, Treatment Adherence
Interventions
Contingency Management (CM), Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)
Behavioral
Lead sponsor
Karen Derefinko, PhD
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 11, 2026, 1:06 PM EDT
Recruiting Early Phase 1 Interventional

A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use

NCT06726200
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine + naloxone (Suboxone), Buprenorphine Injection
Drug
Lead sponsor
Rachel R. Luba
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 11, 2026, 1:06 PM EDT
Completed Phase 2 Interventional Results available

Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone

NCT00637000
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Buprenorphine soluble film, Buprenorphine/naloxone film strip, Placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 11, 2026, 1:06 PM EDT
Completed Phase 2 Interventional Results available

Assessing the Safety of Buprenorphine in People With Sickle Cell Disease

NCT03492099
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
buprenorphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 11, 2026, 1:06 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Medication Maintenance Therapy in Community Pharmacy Settings

NCT04139213
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
buprenorphine/naloxone oral product, injectable naltrexone, Pharmacy maintenance addiction care, oral naltrexone
Drug · Other
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 11, 2026, 1:06 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Clinician Practice Companion to Address Youth Substance Use

NCT07725289
View directory record Official record
Conditions
Substance Use, Substance-Related Disorders, Adolescent Substance Use, Cannabis Use, Opioid Use Disorder, Drug Overdose, Overdose Prevention, Co-occurring Mental Health Conditions
Interventions
Practice Companion
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 24 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 11, 2026, 1:06 PM EDT
Completed Not applicable Interventional

Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia

NCT00539123
View directory record Official record
Conditions
Opiate Dependence
Interventions
behavioral drug and HIV risk reduction counseling (BDRC), abstinence-contingent buprenorphine (ACB)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 11, 2026, 1:06 PM EDT
Withdrawn Phase 3 Interventional

Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects

NCT01713803
View directory record Official record
Conditions
Opioid Dependence
Interventions
Buprenorphine and naloxone
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 11, 2026, 1:06 PM EDT
Recruiting Not applicable Interventional

Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD

NCT06288711
View directory record Official record
Conditions
Opioid Use Disorder, Posttraumatic Stress Disorder
Interventions
Prolonged exposure therapy, Financial incentives, Treatment as usual
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 11, 2026, 1:06 PM EDT
Completed Not applicable Interventional Results available

HIV, Buprenorphine, and the Criminal Justice System

NCT01550341
View directory record Official record
Conditions
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
Interventions
Buprenorphine/naloxone, Placebo Oral Tablet
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 11, 2026, 1:06 PM EDT
Completed No phase listed Observational Results available

Evaluation of Long-term Buprenorphine Plasma Exposure

NCT03752528
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Blood sample collection, Urine sample collection
Diagnostic Test
Lead sponsor
Indivior Inc.
Industry
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
11
States / cities
Hamilton, Alabama • Tampa, Florida • Prairie Village, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 11, 2026, 1:06 PM EDT
Completed No phase listed Observational

Using mHealth to Aid Opioid Medication Adherence Pilot Study

NCT02017041
View directory record Official record
Conditions
Opioid Dependence
Interventions
Medsignals, smartphone app
Device
Lead sponsor
Care Team Solutions
Industry
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Oct 11, 2026, 1:06 PM EDT
Withdrawn Phase 4 Interventional

Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents

NCT01015066
View directory record Official record
Conditions
Opiate Addiction
Interventions
Buprenorphine/naloxone, Naltrexone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
16 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 11, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Results available

Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients

NCT01559454
View directory record Official record
Conditions
Low Back Pain
Interventions
Methadone, Buprenorphine/naloxone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Amherst, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 11, 2026, 1:06 PM EDT
Completed Not applicable Interventional

MySafeRx™: An Integrated Mobile Platform for Buprenorphine Adherence

NCT02778282
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
MySafeRx™
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 39 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Somerville, Massachusetts • Bennington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 11, 2026, 1:06 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone

NCT02666001
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Methadone, Buprenorphine and Norbuprenorphine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Orlando, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 11, 2026, 1:06 PM EDT